Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex

Hoon-Chul Kang1, Young-Mock Lee, Heung Dong Kim

  • 1Department of Pediatrics and Epilepsy Center, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.

Epilepsia
|January 24, 2007
PubMed

Insights

The ketogenic diet (KD) effectively reduced seizures in children with intractable epilepsy and mitochondrial respiratory chain defects. This safe therapy showed significant seizure reduction in most patients, with some becoming seizure-free.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Pediatrics

Background:

  • Intractable childhood epilepsy often presents challenges in management.
  • Mitochondrial respiratory chain (RC) complex defects are associated with severe neurological conditions, including epilepsy.
  • The ketogenic diet (KD) is a high-fat, low-carbohydrate diet used therapeutically for epilepsy.

Purpose of the Study:

  • To assess the clinical efficacy and safety of the KD in children with intractable epilepsy and RC complex defects.
  • To determine the impact of KD on seizure frequency, EEG findings, and medication requirements.
  • To identify adverse reactions associated with KD in this patient population.

Main Methods:

  • Retrospective analysis of 14 children with intractable epilepsy and RC complex defects.
  • Treatment involved a classic KD (4:1 lipid to nonlipid ratio) without initial fasting or fluid restriction.
  • Outcome measures included seizure frequency, EEG, antiepileptic drug count, and adverse events.

Main Results:

  • Seven patients achieved seizure freedom on KD; three maintained this status.
  • Additional patients experienced significant seizure reduction (50-90% or >90%).
  • Four patients, including two with Leigh disease, showed no benefit or discontinued the diet due to complications.

Conclusions:

  • The ketogenic diet is a safe and effective therapeutic option for managing seizures in children with intractable epilepsy and RC complex defects.
  • KD demonstrates significant potential in improving seizure control in this specific pediatric population.
  • Further research may explore optimizing KD protocols for patients with mitochondrial disorders.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...